Supporting Clinical Trials with Early Detection Biomarker Testing
date
October 1, 2024time & location
11:00 AM ET, VirtualThe clinical trial landscape continues to evolve at a rapid pace. New biomarker detection technologies are driving breakthroughs to earlier discoveries and more sensitive diagnostics. With early detection, biomarker testing research can advance disease understanding and management in areas of care such as neurology, oncology, immunology, cardiology, and infectious disease.
Join this webinar to:
- Learn solutions to demanding clinical timelines
- Explore cutting-edge biomarker technologies and their impact on clinical trials
- Gain insights on leveraging biomarkers to advance disease understanding and management
Speaker
Mingwei Zhao, Ph.D.
Sr. Director of Accelerator Services, Quanterix
Mingwei Zhao is an expert in immunoassay development and biomarker research. He began his career at Harvard University, focusing on gene expression and immune responses. At Quanterix Corporation, he advanced Simoa technology and developed ultrasensitive immunoassays. Now, as Senior Director of Lab Services, he oversees custom assay development and manages external relationships. Zhao holds a Bachelor’s in Biology from Wuhan University and a Ph.D. in Molecular Biology and Biochemistry from the Chinese Academy of Sciences.